#TCT2024: @GilbertTangMD, @hahn_rt, et al present the full randomized cohort of the #TRILUMINATE pivotal trial w/ #simpub in #JACC. They find that T-TEER for #TricuspidRegurgitation is: ✅ Safe & effective ⬇️ Reduces TR ⬆️ Improves 6 min walk & #QoL
Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-Year Outcomes From the TRILUMINATE Randomized Cohort.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Oct 2024 – Mar 2025Where it's discussed
-
X / Twitter27 posts
-
News8 articles
-
YouTube4 videos
-
Facebook4 posts
-
Blogs2 articles
-
Bluesky1 posts
AI synopsis
What people are saying
Discussions express strong agreement with the study's positive results, using words like 'promising' and 'effective,' while showing high interest in the procedure's benefits. The engagement is demonstrated through references to detailed outcomes like TR severity reduction and quality of life improvements, and the overall tone underscores a belief that these findings could influence future heart treatments.
Most discussions support the positive findings of the TRILUMINATE study, emphasizing its safety and effectiveness.
The discussions reflect high curiosity about the new treatment and its implications for heart health, showing enthusiasm for the procedure's advancements.
Participants reference specific outcomes like TR reduction, improved quality of life, and technical details, indicating meaningful engagement.
The conversations highlight the significant potential impact of the study, including FDA approval and changes in treatment approaches.
Abstract in brief
- The TRILUMINATE Pivotal trial assessed the effects of tricuspid transcatheter edge-to-edge repair (T-TEER) on reducing tricuspid regurgitation (TR), a significant heart condition linked to increased health risks.
- Involving 572 patients, mostly elderly women with prior heart conditions, the trial found that T-TEER effectively improved quality of life, with nearly half of those treated experiencing significant improvements in heart health assessments.
- Results showed that while the treatment and control groups had similar rates of survival and heart-related surgeries, those who underwent T-TEER had notably better outcomes in TR severity and overall quality of life.
Top posts
Most liked on X and Bluesky#TCT2024: T-TEER was approved by @US_FDA for #TricuspidRegurgitation in 2024 based on interim results of #TRILUMINATE. Full RCT results are now available in #JACC, led by Drs. @GilbertTangMD, @hahn_rt, and team https://t.co/AgDt1dBzck #vhdTR #TEER #CardioX https://t.co/DP4s9sC59o
#TCT2024 ICYMI: #JACC AE Dr. Celina Yong from @StanfordDeptMed talks with #JACCCaseReports EiC Dr. @GilbertTangMD about the full results of the #TRILUMINATE pivotal trial
(11/13) For more on the revolution in structural cardiology, check out #JACC Executive Associate Editor Dr. @aakriti_15's Masterclass with Dr. @MartyBLeon Full Video: https://t.co/zqEwPSvnig https://t.co/HrKNeOM0A9
(4/13) First, Drs. @GilbertTangMD & @hahn_rt, et al publish outcomes from the #TRILUMINATE pivotal trial of tricuspid transcatheter edge-to-edge repair https://t.co/1YQICii7iL #JACC #TEER #vhdTR https://t.co/NSxyp0fSW3
All mentions
Advancements in Tricuspid Regurgitation Treatment via TTVR
In this JACC Journal Club session, we analyze cutting-edge research on tricuspid transcatheter interventions, emphasizing the TRISCEND II trial. Our experts discuss patient selection, procedural techniques, and…
Improving Quality of Life with Transcatheter Tricuspid Valve Replacement
In this JACC Masterclass, Aakriti Gupta MD FACC and Martin B Leon MD FACC discuss the impact of severe tricuspid regurgitation on health status and the TRISCEND II trial findings. They highlight significant improvements…
One-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation
The TRILUMINATE trial evaluates T-TEER's impact on severe tricuspid regurgitation. Results show improved quality of life and reduced TR severity after one year, with no significant difference in mortality or additional…
Efficacy of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation
The TRILUMINATE trial evaluated the impact of T-TEER on reducing tricuspid regurgitation and improving patient quality of life, showing significant benefits in heart health and symptom relief for elderly patients with…
RT @NMCardioVasc:
The TRILUMINATE study shows promising 1-year outcomes for patients with severe tricuspid regurgitation using transcatheter edge-to-edge repair. #HeartHealth #MedicalResearch https://t.co/Af5IUV9xZ6 https://t.co/XPiT7u5734
RT @JACCJournals: (11/13) For more on the revolution in structural cardiology, check out #JACC Executive Associate Editor Dr. @aakriti_15's…
Transcatheter Interventions for Tricuspid Regurgitation | JACC Journal Club American College of Cardiology https://t.co/HmjMGawBvk
TRILUMINATE(および心臓リモデリングを評価したサブ解析)やTRISCEND IIも紹介されてます https://t.co/zl56nZ3eo9 https://t.co/u93QSO57e9 https://t.co/sZ2YhGmdXQ
RT @JACCJournals: (11/13) For more on the revolution in structural cardiology, check out #JACC Executive Associate Editor Dr. @aakriti_15's…
(11/13) For more on the revolution in structural cardiology, check out #JACC Executive Associate Editor Dr. @aakriti_15's Masterclass with Dr. @MartyBLeon Full Video: https://t.co/zqEwPSvnig https://t.co/HrKNeOM0A9
(4/13) First, Drs. @GilbertTangMD & @hahn_rt, et al publish outcomes from the #TRILUMINATE pivotal trial of tricuspid transcatheter edge-to-edge repair https://t.co/1YQICii7iL #JACC #TEER #vhdTR https://t.co/NSxyp0fSW3
RT @JACCJournals: #TCT2024 ICYMI: #JACC AE Dr. Celina Yong from @StanfordDeptMed talks with #JACCCaseReports EiC Dr. @GilbertTangMD about t…
#TCT2024 ICYMI: #JACC AE Dr. Celina Yong from @StanfordDeptMed talks with #JACCCaseReports EiC Dr. @GilbertTangMD about the full results of the #TRILUMINATE pivotal trial
RT @JACCJournals: #TCT2024: T-TEER was approved by @US_FDA for #TricuspidRegurgitation in 2024 based on interim results of #TRILUMINATE. Fu…
RT @JACCJournals: #TCT2024: T-TEER was approved by @US_FDA for #TricuspidRegurgitation in 2024 based on interim results of #TRILUMINATE. Fu…
RT @JACCJournals: #TCT2024: @GilbertTangMD, @hahn_rt, et al present the full randomized cohort of the #TRILUMINATE pivotal trial w/ #simpub…
RT @JACCJournals: #TCT2024: T-TEER was approved by @US_FDA for #TricuspidRegurgitation in 2024 based on interim results of #TRILUMINATE. Fu…
RT @JACCJournals: #TCT2024: T-TEER was approved by @US_FDA for #TricuspidRegurgitation in 2024 based on interim results of #TRILUMINATE. Fu…
#TCT2024: T-TEER was approved by @US_FDA for #TricuspidRegurgitation in 2024 based on interim results of #TRILUMINATE. Full RCT results are now available in #JACC, led by Drs. @GilbertTangMD, @hahn_rt, and team https://t.co/AgDt1dBzck #vhdTR #TEER #CardioX https://t.co/DP4s9sC59o
RT @JACCJournals: #TCT2024: @GilbertTangMD, @hahn_rt, et al present the full randomized cohort of the #TRILUMINATE pivotal trial w/ #simpub…
RT @JACCJournals: #TCT2024: @GilbertTangMD, @hahn_rt, et al present the full randomized cohort of the #TRILUMINATE pivotal trial w/ #simpub…
RT @JACCJournals: #TCT2024: @GilbertTangMD, @hahn_rt, et al present the full randomized cohort of the #TRILUMINATE pivotal trial w/ #simpub…
RT @JACCJournals: #TCT2024: @GilbertTangMD, @hahn_rt, et al present the full randomized cohort of the #TRILUMINATE pivotal trial w/ #simpub…
RT @JACCJournals: #TCT2024: @GilbertTangMD, @hahn_rt, et al present the full randomized cohort of the #TRILUMINATE pivotal trial w/ #simpub…
RT @JACCJournals: #TCT2024: @GilbertTangMD, @hahn_rt, et al present the full randomized cohort of the #TRILUMINATE pivotal trial w/ #simpub…
Triclip T-TEER TR 'Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation' TEER https://t.co/cAE83rjSer
RT @JACCJournals: #TCT2024: @GilbertTangMD, @hahn_rt, et al present the full randomized cohort of the #TRILUMINATE pivotal trial w/ #simpub…
RT @JACCJournals: #TCT2024: @GilbertTangMD, @hahn_rt, et al present the full randomized cohort of the #TRILUMINATE pivotal trial w/ #simpub…
#TCT2024: @GilbertTangMD, @hahn_rt, et al present the full randomized cohort of the #TRILUMINATE pivotal trial w/ #simpub in #JACC. They find that T-TEER for #TricuspidRegurgitation is: ✅ Safe & effective ⬇️ Reduces TR ⬆️ Improves 6 min walk & #QoL